Work

Phase I study of 131I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.10038

Authors: Thomas Cash, Araz Marachelian, Steven G. DuBois, Yueh-Yun Chi, Susan G. Groshen, Anasheh Shamirian, Alina C Stout, Margaret E Macy, Navin R. Pinto, Ami Vijay Desai, Paul M. Sondel, Shahab Asgharzadeh, Brian D. Weiss, Yael P. Mosse, Katherine K. Matthay, Julie R. Park, Kelly C. Goldsmith

Institutions: Emory University, Children's Healthcare of Atlanta, Children's Hospital of Los Angeles, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, University of Southern California, Children's Hospital Colorado, Seattle Children's Hospital, University of Chicago Medical Center, University of Wisconsin–Madison, Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, University of California, San Francisco

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: United Therapeutics Corporation

OpenAlex ID: W4281633748

Cites:

Cited by: 3

Related to: 10